Correction to AbbVie Skin-Treatment Article
July 28 2020 - 6:58PM
Dow Jones News
In AbbVie Inc.'s successful Phase 3 trial of Rinvoq, 26% of
patients receiving a placebo plus topical corticosteroids met a
skin-clearance benchmark, compared with two-thirds to
three-quarters of patients receiving Rinvoq plus topical
corticosteroids. "AbbVie Skin Treatment Successful in Phase 3
Trial" at 8:59 a.m. ET incorrectly said that 11% of the placebo
patients met that skin-clearance benchmark.
(END) Dow Jones Newswires
July 28, 2020 18:43 ET (22:43 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024
